What mood stabilizers are safe for 15-year-old patients with bipolar disorder or major depressive disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For 15-year-old patients with bipolar disorder or major depressive disorder, lithium is the only FDA-approved mood stabilizer for ages 12 and older, and it should be considered as a first-line treatment option, typically starting at a low dose of 300mg daily and gradually increasing based on blood levels and response. Other mood stabilizers like valproate (Depakote) and lamotrigine (Lamictal) can also be considered, although they are not FDA-approved for this age group 1. Second-generation antipsychotics like risperidone, aripiprazole, and quetiapine are also options for adolescents with bipolar disorder, but they should be used with caution due to potential side effects like weight gain and metabolic problems 1.

Some key points to consider when prescribing mood stabilizers to 15-year-old patients include:

  • Regular blood work to check therapeutic levels and monitor for side effects, such as lithium levels, renal and thyroid function, and urinalyses for lithium, and liver function tests, complete blood cell counts, and pregnancy tests for valproate 1
  • Slow titration of lamotrigine to avoid serious rash complications, usually starting at 25mg daily for two weeks before gradually increasing 1
  • Monitoring for extrapyramidal side effects, including tardive dyskinesia, with atypical antipsychotics 1
  • Regular reassessment of treatment plans as the young person develops, taking into account specific symptoms, potential side effects, and medical history 1

Treatment should always be initiated and monitored by a child psychiatrist, and psychotherapy, particularly cognitive behavioral therapy or dialectical behavior therapy, should accompany medication treatment 1. It is also important to advise patients and families about presenting symptoms of potential adverse effects, as periodic monitoring does not ensure that abnormalities will be readily identified 1.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Mood Stabilizers for 15-Year-Old Patients

Mood stabilizers are a crucial part of managing bipolar disorder and major depressive disorder in adolescents. The following mood stabilizers have been studied for their safety and efficacy in this age group:

  • Lithium: Lithium has been shown to be effective in the treatment of bipolar disorder in adults 2, 3. A study on adolescents with bipolar depression found that lithium was effective and relatively well-tolerated in this age group 4.
  • Lamotrigine: Lamotrigine has been studied in adults with bipolar disorder and has been found to be effective in delaying time to intervention for any mood episode 5, 6. However, there is limited research on the use of lamotrigine in adolescents.

Safety Considerations

When prescribing mood stabilizers to 15-year-old patients, it is essential to consider the potential risks and side effects. Lithium, for example, requires blood monitoring due to the risk of toxicity 2. Lamotrigine has been associated with a risk of serious rash, although this is rare 5, 6.

Dosage and Administration

The dosage and administration of mood stabilizers in adolescents may differ from those in adults. For example, the dosage of lamotrigine is titrated over a 6-week period to minimize the risk of serious rash 5, 6. Lithium dosing in adolescents is typically adjusted to achieve a therapeutic serum level 4.

Future Research

More research is needed to fully understand the safety and efficacy of mood stabilizers in adolescents. Controlled studies of lithium and lamotrigine in adolescent bipolar disorder are necessary to provide more definitive answers about their use in this age group 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Open-label lithium for the treatment of adolescents with bipolar depression.

Journal of the American Academy of Child and Adolescent Psychiatry, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.